Takeda files NDA for azilsartan medoxomil in USA, settles Actos patent disputes; Actavis debuts generic Flomax
Leading Japanese drugmaker Takeda Pharmaceutical says that Takeda Global Research & Development Center, USA, has submitted a New Drug Application to the Food and Drug Administration for azilsartan medoxomil (TAK-491), an angiotensin II receptor blocker under investigation for the treatment of hypertension. Discovered by Takeda, the compound is designed to lower blood pressure by blocking the action of angiotensin II.
"The NDA submission for azilsartan medoxomil is built upon a robust data package and is a significant milestone for Takeda," said Nancy Joseph-Ridge, general manager of Takeda's Pharmaceutical Development Division. The company is looking to replace its current blockbuster antihypertensive Blopress (candesartan cilexetil), which will lose US patent protection in 2012.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Generics
| Headless Content Management with Blaze